A novel therapy with zoledronic acid od bone metastasis in advanced prostate cancer reflecting molecular investigations
Journal Title: Współczesna Onkologia - Year 2006, Vol 10, Issue 1
Abstract
Prostate cancer continues to represent a major therapeutic challenge. There is still observed a large number of patients worldwide. This malignancy is mainly diagnosed in industrialized countries. Dietary factors, lifestyle – related factors, and androgens have long been recognized as contributors to the risk of prostate cancer. During the last 10 years, molecular studies have provided unexpected molecular events showing the prostate cancer tumorigenesis and progression. The modern therapy of prostate cancer relies on hormonal therapy. One step further for treatment of androgen-independent prostate cancer means chemotherapy based upon docetaxel, estramustine, and glucocorticoids. Bone metastases are frequent in prostate cancer. One of the drawbacks of long-term hormone therapy has been reported in recent studies as the changed bone metabolism. Long-term treatment of zoledronic acid is safe and gives substantial clinical benefits for men with metastatic hormone-refractory prostate cancer. The huge challenge still exists to seek novel agents which will offer better results in the course of the entity. Imatinib is a well-known agent blocking the function of protein kinases, and one of them is associated with PDGF (platelet-derived growth factor) receptor. The latter could become a target in the treatment of prostate cancer. Vitamin D and its metabolites may improve results of chemotherapy used to control prostate cancer.
Authors and Affiliations
Gabriel Wcisło, Sylwia Oborska, Lubomir Bodnar, Katarzyna Szarlej-Wcisło, Cezary Szczylik
Keywords
Related Articles
- EP ID EP83626
- DOI -
- Views 64
- Downloads 0
Miejscowe powikłania kolostomii u osób w wieku podeszłym – badanie retrospektywne
Polska pod względem demograficznym należy do starszych społeczeństw. Wśród osób w wieku podeszłym stwierdza się znaczny wzrost chorób nowotworowych przewodu pokarmowego, a szczególnie jelita grubego. Nadal u części cho...
Screening in colorectal cancer (CRC)
Colorectal cancer (CRC) is one of major health problems in Poland. Every year about 11 000 new cases of CRC (EU about 220 000) are diagnosed; the number of deaths approaches 8 000 (EU 112 000). Five-year free disease sur...
Rola IMRT w redukcji dawki promieniowania w odbytnicy w trakcie radykalnej radioterapii raka gruczołu krokowego
Cel pracy: Celem pracy było porównanie dwóch technik napromieniania raka gruczołu krokowego – IMRT vs 3D- -CRT – pod względem dawek zdeponowanych w odbytnicy. Materiał i metody: W badaniu wykorzystano dane (przekroje t...
The role of oestrogenes in carcinogenesis.
Both oestrogens and their metabolites are believed to be etiological factors in breast, uterine and ovarian carcinomas. Those hormones stimulate the proliferation of cells, which proceeded by DNA replication, offers the...
Bone marrow suppression induced by systemic radionuclides (153Sm) in metastatic breast cancer patients with bone metastases, its impact on subsequent chemotherapy
Introduction: Bone metastases are present in approximately 75 percent of breast cancer patients, therefore bones are the most frequent localization of metastases and the only site of metastatic spread in many patients....